<DOC>
	<DOCNO>NCT00765479</DOCNO>
	<brief_summary>RATIONALE : Soy protein may help prevent prostate cancer recurrence patient undergone surgery prostate cancer . PURPOSE : This randomized phase II/III trial study well soy protein work compare placebo prevent recurrent cancer patient undergone surgery stage II prostate cancer .</brief_summary>
	<brief_title>Soy Protein Preventing Recurrent Cancer Patients Who Have Undergone Surgery Stage II Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether soy protein isolate reduces PSA failure rate time PSA failure within 2 year follow radical prostatectomy patient high risk prostate cancer recurrence . - Determine effect soy protein isolate intermediate biomarkers steroid hormone axis ( testosterone , estradiol , SHBG ) thyroid activity ( T3 T4 ) . - Determine effect soy protein isolate intermediate biomarkers apoptosis ( soluble Fas Fas-ligand ) , angiogenesis ( VEGF bFGF ) , antioxidant activity ( 8-isoprostanes ) , IGF axis ( IGF-1 IGFBP-3 ) . - Compare patient equol producer non-producers . OUTLINE : This multicenter study . Patients stratify accord hospital/clinic site ( NYU vs UIC Jesse Brown VA Medical Center v site ) , number high-risk characteristic ( 1 v &gt; 1 ) , race ( African American v non-African American [ i.e. , non-Hispanic White , Hispanic , Asian , ] ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral soy protein isolate beverage daily . - Arm II : Patients receive oral casein placebo beverage daily . Treatment arm continue 2 year absence disease progression unacceptable toxicity . Blood sample collect periodically biomarker laboratory study . Samples analyzed measure PSA level Tosoh PSA assay ; cholesterol level ; isoflavone equol concentration HPLC ESA ; indicator steroid hormone axis ( testosterone , estradiol , SHBG ) , indicator thyroid activity ( T3 T4 ) , indicator apoptosis ( soluble Fas Fas-ligand ) , indicator angiogenesis ( VEGF bFGF ) , indicator oxidative stress ( 8-isoprostanes ) , indicator IGF axis ( IGF-1 IGFBP-3 ) ELISA .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis prostate cancer Clinically localize ( T1c T2 ) disease At high risk recurrence , define ≥ 1 following : Preoperative PSA &gt; 20.0 ng/mL Seminal vesicle invasion Extracapsular extension ( exclude bladder neck ) Positive surgical margin ( exclude apical margin ) Micrometastases remove pelvic lymph node Final Gleason score ≥ 8 Must undergone radical prostatectomy prostate cancer within past 4 month Must undetectable PSA ( &lt; 0.07 ng/mL ) baseline , measure Tosoh PSA assay No clinical evidence locally recurrent metastatic disease PATIENT CHARACTERISTICS : No significant intake soy ( i.e. , week ) baseline include , limited , follow : Vegetarians regularly consume soy product ( e.g. , tofu ) Individuals customary Asian dietary habit , include regular intake soy product Individuals use soybased milk replacement No anemia , iron deficiency problem , subclinical iron deficiency baseline No diabetes No thyroid disease No requirement sodiumfree diet No substantive tendency constipate ( i.e. , ≥ grade 2 constipation experience regularly ) No medical problem would preclude consumption soy contain beverage powder , include allergy soy ( milk protein ) No concurrent major disease , include major mental disease major substance abuse problem No significant side effect medication PRIOR CONCURRENT THERAPY : See Disease Characteristics No concurrent radiotherapy hormonal therapy No concurrent adjuvant therapy prostate cancer</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
</DOC>